Exosomes in esophageal cancer: a promising frontier for liquid biopsy in diagnosis and therapeutic monitoring DOI Creative Commons

Ren Zihan,

Cao Jingsi,

Ding Lingwen

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 17, 2024

Esophageal cancer is a common and lethal digestive system malignancy, both treatment efficacy patient survival rates face significant challenges. In recent years, exosomes have emerged as crucial mediators of intercellular communication, demonstrating tremendous clinical potential, particularly in the diagnosis, treatment, prognostic evaluation esophageal cancer. These not only serve biomarkers for early diagnosis prognosis but also modulate tumor growth, metastasis, drug resistance by delivering bioactive molecules. Importantly, can act carriers cancer-related therapeutic agents, optimizing gene therapy strategies to enhance while reducing toxicity side effects. Despite facing challenges applications such purification, enrichment, standardization analytical methods, maintain broad prospects application with potential significantly improve outcomes quality life. This review focuses on innovative role cancer, exploring their value safety disease monitoring assessment response. Furthermore, this study outlines limitations transitioning exosome research from basic studies applications, well solutions future directions address these obstacles.

Language: Английский

Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine DOI Creative Commons
Yanhong Duo, Lei Han, Yaoqiang Yang

et al.

Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(20), P. 11242 - 11347

Published: Oct. 9, 2024

Biopsy, including tissue and liquid biopsy, offers comprehensive real-time physiological pathological information for disease detection, diagnosis, monitoring. Fluorescent probes are frequently selected to obtain adequate on processes in a rapid minimally invasive manner based their advantages biopsy. However, conventional fluorescent have been found show aggregation-caused quenching (ACQ) properties, impeding greater progresses this area. Since the discovery of aggregation-induced emission luminogen (AIEgen) promoted advancements molecular bionanomaterials owing unique high quantum yield (QY) signal-to-noise ratio (SNR),

Language: Английский

Citations

18
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers DOI
Yuan Li,

Silei Sui,

Ajay Goel

et al.

Seminars in Cancer Biology, Journal Year: 2024, Volume and Issue: 99, P. 5 - 23

Published: Feb. 1, 2024

Language: Английский

Citations

12
NMR and MS reveal characteristic metabolome atlas and optimize esophageal squamous cell carcinoma early detection DOI Creative Commons
Yan Zhao,

Changchun Ma,

Rongzhi Cai

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: March 19, 2024

Metabolic changes precede malignant histology. However, it remains unclear whether detectable characteristic metabolome exists in esophageal squamous cell carcinoma (ESCC) tissues and biofluids for early diagnosis. Here, we conduct NMR- MS-based metabolomics on 1,153 matched ESCC tissues, normal mucosae, pre- one-week post-operative sera urines from 560 participants across three hospitals, with machine learning WGCNA. Aberrations 'alanine, aspartate glutamate metabolism' proved to be prevalent throughout the evolution, consistently identified by NMR MS, reflected 16 serum 10 urine metabolic signatures both discovery validation sets. NMR-based simplified panels of any five or metabolites outperform clinical serological tumor markers (AUC = 0.984 0.930, respectively), are effective distinguishing early-stage test set (serum accuracy 0.994, 0.879). Collectively, biofluid screening can reveal events feasible detection (ChiCTR2300073613).

Language: Английский

Citations

10
Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories DOI
Álvaro González, Silvia López-Borrego, Amaia Sandúa

et al.

Critical Reviews in Clinical Laboratory Sciences, Journal Year: 2024, Volume and Issue: 61(6), P. 435 - 457

Published: Feb. 15, 2024

Extracellular vesicles (EVs) are nano-sized particles secreted by most cells. They transport different types of biomolecules (nucleic acids, proteins, and lipids) characteristic their tissue or cellular origin that can mediate long-distance intercellular communication. In the case cancer, EVs participate in tumor progression modifying microenvironment, favoring immune tolerance metastasis development. Consequently, have great potential liquid biopsy for cancer diagnosis, prognosis follow-up. addition, could a role treatment as targeted drug delivery system. The intense research EV field has resulted hundreds patents creation biomedical companies. However, methodological issues heterogeneity composition hampered advancement validation trials development EV-based diagnostic therapeutic products. only few biomarkers moved from to clinical laboratories, such ExoDx Prostate IntelliScore (EPI) test, CLIA/FDA-approved prostate test. number large-scale multicenter studies would clearly define biomarker performance is limited. this review, we will critically describe EVs, methods enrichment characterization, biological cancer. Then, specially focus on parameters be considered translation biology clinic laboratory, advances already made related diagnosis treatment, still pending solved before used routine tool oncology.

Language: Английский

Citations

9
Development a glycosylated extracellular vesicle-derived miRNA Signature for early detection of esophageal squamous cell carcinoma DOI Creative Commons
Jianlin Chen, Yue Zheng, Zhen Wang

et al.

BMC Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 23, 2025

Language: Английский

Citations

1
Big data and artificial intelligence in cancer research DOI
Xifeng Wu, Wenyuan Li, Huakang Tu

et al.

Trends in cancer, Journal Year: 2023, Volume and Issue: 10(2), P. 147 - 160

Published: Nov. 16, 2023

Language: Английский

Citations

22
Liquid biopsy: An arsenal for tumour screening and early diagnosis DOI
Qi Zhang, Xiaoli Zhang,

Peipei Xie

et al.

Cancer Treatment Reviews, Journal Year: 2024, Volume and Issue: 129, P. 102774 - 102774

Published: June 3, 2024

Language: Английский

Citations

7
Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine DOI Creative Commons
Xingli Dong, Yusheng Lin, Kai Li

et al.

Clinical Chemistry and Laboratory Medicine (CCLM), Journal Year: 2024, Volume and Issue: unknown

Published: June 19, 2024

Abstract Extracellular vesicles (EVs) represent a diverse class of nanoscale membrane actively released by cells. These EVs can be further subdivided into categories like exosomes and microvesicles, based on their origins, sizes, physical attributes. Significantly, disease-derived have been detected in virtually all types body fluids, providing comprehensive molecular profile cellular origins. As result, are emerging as valuable addition to liquid biopsy techniques. In this collective statement, the authors share current perspectives EV-related research product development, with shared commitment translating newfound knowledge clinical applications for cancer other diseases, particularly disease biomarkers. The consensus within document revolves around overarching recognition merits, unresolved questions, existing challenges surrounding EVs. This manuscript is collaborative effort led Committee Exosomes, Society Tumor Markers, Chinese anti-Cancer Association, aimed at expediting cultivation robust scientific clinically applicable breakthroughs propelling field forward greater swiftness efficacy.

Language: Английский

Citations

6
MiR-3682-3p promotes esophageal cancer progression by targeting FHL1 and activating the Wnt/β-catenin signaling pathway DOI

Yuxin Cai,

Lingling Xia,

Hangjia Zhu

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 119, P. 111155 - 111155

Published: March 31, 2024

Language: Английский

Citations

4
Nitric Oxide-Producing Multiple Functional Nanoparticle Remodeling Tumor Microenvironment for Synergistic Photodynamic Immunotherapy against Hypoxic Tumor DOI
Shuyu Xu, Xinxin Xie, Ping He

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 6, 2025

The treatment of pancreatic cancer faces significant challenges due to connective tissue hyperplasia and severe hypoxia. Unlike oxygen-dependent Type II photosensitizers, I photosensitizers can produce a substantial amount reactive oxygen species, even under hypoxic conditions, making them more suitable for photodynamic therapy cancer. However, the dense extracellular matrix limits penetration efficiency presence immunosuppressive cells in tumor microenvironment reduces therapeutic effect. To address these challenges, we designed photoimmunotherapeutic M1@PAP nanoparticles composed photosensitizer anti-PD-L1 siRNA (siPD-L1), which was encapsulated into M1 macrophage membrane vesicles. In this system, pyropheophorbide-a (PPA) covalently conjugated poly-l-arginine (Arg9). Notably, it capable generating sufficient superoxide anions thereby functioning as photosensitizer. Furthermore, Arg9 acted nitric oxide (NO) donor, enhancing nanophotosensitizer by inhibiting cancer-associated fibroblast (CAF) activation decomposing matrix. Additionally, vesicles provided active targeting capabilities reeducated immunosuppressed M2 macrophages. reversal further promoted efficacy immunotherapy, showing great potential synergistic immunotherapy against tumor.

Language: Английский

Citations

0